Terry M Nolan1, Michael D Nissen2, Aftab Naz3, Julie Shepard4, Lisa Bedell5, Matthew Hohenboken5, Tatjana Odrljin5, Peter M Dull5. 1. Vaccine and Immunisation Research Group (VIRGo); Melbourne School of Population and Global Health; University of Melbourne and Murdoch Children's Research Institute; Melbourne, VIC Australia. 2. Queensland Paediatric Infectious Diseases Laboratory; Queensland Children's Medical Research Institute, Royal Children's Hospital; Brisbane, QLD Australia. 3. Madera Family Medical Group; Madera, CA USA. 4. Ohio Pediatric Research Association; Vandalia, OH USA. 5. Novartis Vaccines and Diagnostics; Cambridge, MA USA.
Abstract
BACKGROUND: Infants are at the highest risk for meningococcal disease and a broadly protective and safe vaccine is an unmet need in this youngest population. We evaluated the immunogenicity and safety of a 4-dose infant/toddler regimen of MenACWY-CRM given at 2, 4, 6, and 12 months of age concomitantly with pentavalent diphtheria-tetanus-acellular pertussis-Hemophilus influenzae type b-inactivated poliovirus-combination vaccine (DTaP-IPV/Hib), hepatitis B vaccine (HBV), 7- or 13-valent conjugate pneumococcal vaccine (PCV), and measles, mumps, and rubella vaccine (MMR). RESULTS: Four doses of MenACWY-CRM induced hSBA titers ≥8 in 89%, 95%, 97%, and 96% of participants against serogroups A, C, W-135, and Y, respectively. hSBA titers ≥8 were present in 76-98% of participants after the first 3 doses. A categorical linear analysis incorporating vaccine group and study center showed responses to routine vaccines administered with MenACWY-CRM were non-inferior to routine vaccines alone, except for seroresponse to the pertussis antigen fimbriae. The reactogenicity profile was not affected when MenACWY-CRM was administered concomitantly with routine vaccines. CONCLUSION: MenACWY-CRM administered with routine concomitant vaccinations in young infants was well tolerated and induced highly immunogenic responses against each of the serogroups without significant interference with the immune responses to routine infant vaccinations. METHODS:Healthy 2 month old infants were randomized to receive MenACWY-CRM with routine vaccines (n = 258) or routine vaccines alone (n = 271). Immunogenicity was assessed by serum bactericidal assay using human complement (hSBA). Medically attended adverse events (AEs), serious AEs (SAEs) and AEs leading to study withdrawal were collected throughout the study period.
RCT Entities:
BACKGROUND:Infants are at the highest risk for meningococcal disease and a broadly protective and safe vaccine is an unmet need in this youngest population. We evaluated the immunogenicity and safety of a 4-dose infant/toddler regimen of MenACWY-CRM given at 2, 4, 6, and 12 months of age concomitantly with pentavalent diphtheria-tetanus-acellular pertussis-Hemophilus influenzae type b-inactivated poliovirus-combination vaccine (DTaP-IPV/Hib), hepatitis B vaccine (HBV), 7- or 13-valent conjugate pneumococcal vaccine (PCV), and measles, mumps, and rubella vaccine (MMR). RESULTS: Four doses of MenACWY-CRM induced hSBA titers ≥8 in 89%, 95%, 97%, and 96% of participants against serogroups A, C, W-135, and Y, respectively. hSBA titers ≥8 were present in 76-98% of participants after the first 3 doses. A categorical linear analysis incorporating vaccine group and study center showed responses to routine vaccines administered with MenACWY-CRM were non-inferior to routine vaccines alone, except for seroresponse to the pertussis antigen fimbriae. The reactogenicity profile was not affected when MenACWY-CRM was administered concomitantly with routine vaccines. CONCLUSION: MenACWY-CRM administered with routine concomitant vaccinations in young infants was well tolerated and induced highly immunogenic responses against each of the serogroups without significant interference with the immune responses to routine infant vaccinations. METHODS: Healthy 2 month old infants were randomized to receive MenACWY-CRM with routine vaccines (n = 258) or routine vaccines alone (n = 271). Immunogenicity was assessed by serum bactericidal assay using human complement (hSBA). Medically attended adverse events (AEs), serious AEs (SAEs) and AEs leading to study withdrawal were collected throughout the study period.
Authors: J M MacLennan; F Shackley; P T Heath; J J Deeks; C Flamank; M Herbert; H Griffiths; E Hatzmann; C Goilav; E R Moxon Journal: JAMA Date: 2000-06-07 Impact factor: 56.272
Authors: Matthew D Snape; Dominic F Kelly; Ben Green; E Richard Moxon; Ray Borrow; Andrew J Pollard Journal: Pediatr Infect Dis J Date: 2005-02 Impact factor: 2.129
Authors: Caroline L Trotter; Manosree Chandra; Rosa Cano; Amparo Larrauri; Mary E Ramsay; Carina Brehony; Keith A Jolley; Martin C J Maiden; Sigrid Heuberger; Matthias Frosch Journal: FEMS Microbiol Rev Date: 2006-12-01 Impact factor: 16.408
Authors: Caroline L Trotter; Nick J Andrews; Edward B Kaczmarski; Elizabeth Miller; Mary E Ramsay Journal: Lancet Date: 2004 Jul 24-30 Impact factor: 79.321
Authors: Geraldine Blanchard-Rohner; Matthew D Snape; Dominic F Kelly; Daniel O'Connor; Tessa John; Elizabeth A Clutterbuck; Brigitte Ohene-Kena; Chaam L Klinger; Tatjana Odrljin; Andrew J Pollard Journal: Vaccine Date: 2013-04-06 Impact factor: 3.641
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi Journal: Pediatr Nephrol Date: 2015-04-11 Impact factor: 3.714
Authors: Jessica R MacNeil; Lorry Rubin; Lucy McNamara; Elizabeth C Briere; Thomas A Clark; Amanda C Cohn Journal: MMWR Morb Mortal Wkly Rep Date: 2014-06-20 Impact factor: 17.586